Free Trial
ASX:ACR

Acrux (ACR) Stock Price, News & Analysis

Acrux logo

About Acrux Stock (ASX:ACR)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
11.66%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Receive ACR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter.

ACR Stock News Headlines

Acrux Limited Expands Market Presence with New Securities
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Acrux Limited Lists New Shares on ASX
Acrux Limited Expands U.S. Market with New Ointment
See More Headlines

ACR Stock Analysis - Frequently Asked Questions

Acrux Limited (ASX:ACR) issued its quarterly earnings data on Thursday, February, 21st. The company reported ($0.02) EPS for the quarter. Acrux had a negative trailing twelve-month return on equity of 96.89% and a negative net margin of 113.93%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrux investors own include Altimmune (ALT), ANZ Group (ANZ), Lynas Rare Earths (LYC), MV Oil Trust (MVO), Organigram (OGI), BHP Group (BHP) and Beacon Roofing Supply (BECN).

Company Calendar

Last Earnings
2/21/2019
Today
12/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
CIK
N/A
Fax
N/A
Employees
2,018
Year Founded
N/A

Profitability

Net Income
$-5,800,000.00
Net Margins
-113.93%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.09 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.21
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (ASX:ACR) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners